Helix BioPharma Corp. (HBPCF)

OTCMKTS · Delayed Price · Currency is USD
0.4500
0.00 (0.00%)
Mar 31, 2025, 4:00 PM EST
226.80%
Market Cap 29.51M
Revenue (ttm) n/a
Net Income (ttm) -6.78M
Shares Out n/a
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000
Average Volume 20
Open 0.6600
Previous Close 0.4500
Day's Range 0.4500 - 0.6600
52-Week Range 0.1400 - 0.9200
Beta -0.85
RSI 48.16
Earnings Date Mar 14, 2025

About Helix BioPharma

Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol HBPCF
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

News

Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting

March 26, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a nea...

5 days ago - TheNewswire

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025

March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...

14 days ago - TheNewswire

Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain

March 11, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...

21 days ago - TheNewswire

Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts

March 6, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near...

26 days ago - TheNewswire

Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a ne...

4 weeks ago - TheNewswire

Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

February 24, 2025 - (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a ...

5 weeks ago - TheNewswire

Helix Biopharma appoints James Murphy as CFO

Helix BioPharma appoints James Murphy as Chief Financial Officer, previously a consultant with Danforth Advisors.

3 months ago - Seeking Alpha

Helix Biopharma announces CFO resignation

5 months ago - Seeking Alpha

Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.

VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Compa...

3 years ago - Accesswire

Helix Biopharma Corp. Closes Private Placement

RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...

3 years ago - Accesswire

Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...

3 years ago - Accesswire

Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription

RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-o...

3 years ago - Accesswire

Helix Biopharma Corp. Announces Management and Board Changes

RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...

3 years ago - Accesswire

Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...

3 years ago - Accesswire

Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board

RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Offi...

3 years ago - Accesswire

CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

(This release corrects the release that was posted earlier on March 11, 2022 due to the incorrect company logo being added. This release adds the corrected logo) RICHMOND HILL, ON / ACCESSWIRE / March...

3 years ago - Accesswire

Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm...

3 years ago - Accesswire

Helix BioPharma Corp. Provides Corporate Update

RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and...

3 years ago - Accesswire

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the preve...

3 years ago - Accesswire

Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results

RICHMOND HILL, ON / ACCESSWIRE / December 9, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field...

3 years ago - Accesswire

Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update

RICHMOND HILL, ON / ACCESSWIRE / November 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and...

3 years ago - Accesswire

Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update

RICHMOND HILL, ON / ACCESSWIRE / November 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and...

3 years ago - Accesswire

Helix BioPharma Corp. Provides Bi-Weekly MCTO Status Update

RICHMOND HILL, ON / ACCESSWIRE / November 1, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and ...

3 years ago - Accesswire

Helix BioPharma Corp. Announces Delay of Annual Filings

RICHMOND HILL, ON / ACCESSWIRE / October 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and ...

3 years ago - Accesswire